Results 111 to 120 of about 709 (171)
Clinical development of oxamniquine in Egypt.
Revista do Instituto de Medicina Tropical de Sao Paulo, 1981 M, Saif, A, Gaber
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Determination of Oxamniquine in Serum
Journal of Pharmaceutical Sciences, 1977A method for the analysis of oxamniquine in serum (or plasma), sensitive to 10 ng/ml, was developed. Oxamniquine and a close structural analog as the internal standard were extracted from serum with ether. After derivatization with N,O-bis(trimethylsilyl)acetamide, oxamniquine was determined as its trimethylsilyl ether derivative by GLC using an ...
N M, Woolhouse, P R, Wood
exaly +3 more sources
Synthesis and evaluation of new oxamniquine derivatives
International Journal of Pharmaceutics, 2002Oxamniquine derivatives were synthesized and evaluated as novel schistosomicide agents. Oxamniquine (1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-6-quinolinemethanol) was submitted to the Mannich reaction, using formaldehyde, paraformaldehyde and acetaldehyde as reagents, and gave three unexpected products: two of them were cyclized on ...
Pedro Luiz Silva Pinto +2 more
exaly +3 more sources
Fluorimetric determination of oxamniquine in biological fluids
Il Farmaco, 1999A highly sensitive and specific fluorimetric method was developed for the determination of oxamniquine in biological fluids (urine and plasma). The proposed method is based on the reduction of oxamniquine using zinc/calcium chloride to obtain its nitroso derivative.
, M Rizk
exaly +3 more sources
Determination of oxamniquine in capsules by HPLC
Journal of Pharmaceutical and Biomedical Analysis, 2001A sensitive, accurate, reliable and easy method was developed for the quantification of oxamniquine in capsules using high-performance liquid chromatography (HPLC) with UV detection. This technique provided conditions for the separation of the active ingredient from the dosage form by extraction in methanol.
Pierri, E. G. +2 more
exaly +4 more sources
The metabolism of oxamniquine in the gut wall
Xenobiotica, 19801. The extent of metabolism of oxamniquine, 6-hydroxymethyl-7-nitro-2-isopropylaminomethyl-1,2,3,4-tetrahydroquinoline, in the gut of the dog has been studied using an intestinal preparation which allows collection of the outflow from the portal vein. 2.
B, Kaye, D W, Roberts
openaire +2 more sources
Binding of oxamniquine to the DNA of schistosomes
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989Hycanthone-sensitive and hycanthone-resistant schistosomes (which are also sensitive and resistant to oxamniquine) were exposed in vitro to tritium-labelled oxamniquine. The initial uptake of the drug into the schistosomes was essentially the same for the 2 strains.
L, Pica-Mattoccia, D, Cioli, S, Archer
openaire +2 more sources
Pharmacokinetics of oxamniquine in rabbit and rat
European Journal of Drug Metabolism and Pharmacokinetics, 1996The pharmacokinetics of the schistosomicidal agent oxamniquine (6-hydroxmethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetra hydroquinoline) were studied in 8 (4 male, 4 female) New Zealand White rabbits and 5 female Wistar rats, following intravenous administration (15 mg/kg).
Kokwaro, GO, Indalo, Anne A, Taylor, G
openaire +2 more sources
2023
This chapter explores the development of oxamniquine by Pfizer pharmaceuticals, which the chapter uses as an example of how traditional strategies can be used in the development of a drug where the molecular target is unknown. It describes oxamniquine as an important drug in developing countries.
openaire +1 more source
This chapter explores the development of oxamniquine by Pfizer pharmaceuticals, which the chapter uses as an example of how traditional strategies can be used in the development of a drug where the molecular target is unknown. It describes oxamniquine as an important drug in developing countries.
openaire +1 more source